Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

By G. Lenz, George W. Wright, N. Emre, H. Kohlhammer, S. Dave, R. Davis, Shannon A. Carty, L. Lam, A. Shaffer, Wenming Xiao and 15 more. Proceedings of the National Academy of Sciences of the United States of America, 2008

1,040 citations recorded by the source corpus.

Subfields: Genetics, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/2f0d0bd5c110e9abddb5774ee37dc7915e86abb4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. R. Dalla-Favera
2. Gregory J. Hannon
3. Sivaraman Balakrishnan

In Oncology

1. R. Dalla-Favera
2. Scott W. Lowe
3. J. Campisi

In Pathology and Forensic Medicine

1. R. Dalla-Favera

Citations in the corpus

• miR-19 is a key oncogenic component of mir-17-92. (2009, result): “In line with this hypothesis, a recent study described a subset of DLBCLs in which the amplification of mir-17-92 and the deletion of PTEN are mutually exclusive (Lenz et al. 2008).”
• Finding and Leveraging Structure in Learning Problems (2012, methodology): “We apply our non-linear CCA models to a data set of comparative genomic hybridization (CGH) and gene expression measurements from 203 diffuse large B-cell lymphoma (DLBCL) biopsy samples [127].”
• Role of Bruton’s tyrosine kinase in B cells and malignancies (2018, background): “The mechanisms of PTEN inactivation include mutation, deletion or amplification of the miR17–92 microRNA cluster that downregulates PTEN expression [175, 176].”
• Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012, background): “The activated B-cell (ABC) subtype has been shown to have a worse prognosis when compared with germinal centre B-cell (GCB) in patients treated by R-CHOP [8].”
• MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. (2013, background): “Our results show that MYC/BCL2 co-expression is associated with a poor prognosis and is more common in the ABC-DLBCL.”
• Hierarchical Information Clustering by Means of Topologically Embedded Graphs (2011, neutral): “Indeed, various studies have attempted to highlight genetically significant genes that can be of clinical significance to improve the DLBCL patients’ diagnosis and clinical treatments [44,46–51].”
• Multi-omics Data Integration, Interpretation, and Its Application (2020, methodology): “32 Sparse CCA was performed on the whole gene expression data and CGH data for a given chromosome “i.” The canonical variables obtained were highly correlated validating the sparsity constraint.”
• Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation (2011, background): “The predominance of point mutations over CNAs is notable, as it is unusual com pared with most cancer types (Mullighan et al., 2007; Lenz et al., 2008; Parsons et al., 2011).”
• Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma (2011, background): “These subtypes are associated in part with distinct genetic lesions, indicating the involvement of separate oncogenic pathway”